These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 1599805)
1. Development of immunotherapeutic strategies for the treatment of malignant neoplasms. Talmadge JE Biotherapy; 1992; 4(3):215-36. PubMed ID: 1599805 [TBL] [Abstract][Full Text] [Related]
2. Development of immunotherapeutic strategies for the treatment of malignant neoplasia. Talmadge JE Pathol Immunopathol Res; 1989; 8(5-6):250-75. PubMed ID: 2699034 [TBL] [Abstract][Full Text] [Related]
3. Immunotherapeutic strategies for neoplasia. Talmadge JE Dev Biol Stand; 1992; 77():17-28. PubMed ID: 1426659 [No Abstract] [Full Text] [Related]
4. Biological response modifiers: preclinical and clinical results. Talmadge JE; Clark J Cancer Chemother Biol Response Modif; 1987; 9():454-72. PubMed ID: 3079413 [No Abstract] [Full Text] [Related]
5. Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer. Tahara H; Lotze MT Gene Ther; 1995 Mar; 2(2):96-106. PubMed ID: 7719935 [TBL] [Abstract][Full Text] [Related]
6. Assessment of biological responses: what to measure and when. Maluish AE; Herberman RB Cancer Treat Rep; 1985 Oct; 69(10):1165-9. PubMed ID: 3899356 [TBL] [Abstract][Full Text] [Related]
7. Biochemical modulation of cytotoxic drugs by cytokines: molecular mechanisms in experimental oncology. Kreuser ED; Wadler S; Thiel E Recent Results Cancer Res; 1995; 139():371-82. PubMed ID: 7597304 [TBL] [Abstract][Full Text] [Related]
9. Biological Response Modifier in Cancer Immunotherapy. Liu R; Luo F; Liu X; Wang L; Yang J; Deng Y; Huang E; Qian J; Lu Z; Jiang X; Zhang D; Chu Y Adv Exp Med Biol; 2016; 909():69-138. PubMed ID: 27240457 [TBL] [Abstract][Full Text] [Related]
10. Cancer therapy by biological response modifiers. Herberman RB Arzneimittelforschung; 1987 Feb; 37(2A):246-50. PubMed ID: 2436633 [TBL] [Abstract][Full Text] [Related]
11. Ex vivo and in vivo characterization of biological response modifiers (BRMs). Masihi KN; Talmadge JE Dev Biol Stand; 1992; 77():143-5. PubMed ID: 1426655 [No Abstract] [Full Text] [Related]
12. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
13. [Interactions of radiation and biological response modifiers (BRMs) in the treatment of malignant tumor]. Mitsuhashi N; Takahashi M; Okazaki A; Niibe H Gan No Rinsho; 1990 Oct; 36(13):2272-7. PubMed ID: 2250347 [TBL] [Abstract][Full Text] [Related]
14. [Combination of chemotherapy and immunotherapy in man--review]. Ohnuma T Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1428-36. PubMed ID: 1697154 [TBL] [Abstract][Full Text] [Related]
15. Biological Response Modifiers Programme and cancer chemotherapy. Oldham RK Int J Tissue React; 1982; 4(3):173-88. PubMed ID: 6183193 [TBL] [Abstract][Full Text] [Related]
17. Practical considerations for the establishment of a screening procedure for the assessment of biological response modifiers. Talmadge JE; Oldham RK; Fidler IJ J Biol Response Mod; 1984; 3(1):88-109. PubMed ID: 6707701 [TBL] [Abstract][Full Text] [Related]
19. Cancer therapy with combinations of biological response modifiers and cytotoxics: an update. Borden EC; Creekmore SP Cancer Cells; 1990 Jul; 2(7):217-20. PubMed ID: 2204387 [TBL] [Abstract][Full Text] [Related]